We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-21.08%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$245M
AUM Growth
-$105M
(-30%)
Cap. Flow
-$36.6M
Cap. Flow
% of AUM
-14.91%
Top 10 Holdings %
Top 10 Hldgs %
79.64%
Holding
33
New
3
Increased
11
Reduced
4
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$12.3M |
| 2 |
AtriCure
ATRC
|
+$10.1M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$8.23M |
| 4 |
McKesson
MCK
|
+$6.24M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$2.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$27.8M |
| 2 |
CORI
Corium International, Inc.
CORI
|
+$13.6M |
| 3 |
Gilead Sciences
GILD
|
+$13.5M |
| 4 |
Pacira BioSciences
PCRX
|
+$7.37M |
| 5 |
HOLX
Hologic
HOLX
|
+$6.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.71% |
| 2 | Industrials | 6.36% |
| 3 | Consumer Discretionary | 4.51% |
| 4 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Glaukos
GKOS
$9.83B
| – | – |
-75,000
| Closed | -$4.87M |
|
|
27
Labcorp
LH
$25B
| – | – |
-186,240
| Closed | -$27.8M |
|
28
PUT
iShares S&P 100 ETF
OEF
$20.1B
| – | – |
-7,000
| Closed | -$539K |
|
|
29
Pacira BioSciences
PCRX
$1.04B
| – | – |
-150,000
| Closed | -$7.37M |
|
30
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| – | – |
-1,500
| Closed | -$294K |
|
|
MODN
31
DELISTED
MODEL N, INC.
MODN
| – | – |
-100,000
| Closed | -$1.58M |
|
|
MDCO
32
PUT
DELISTED
Medicines Co
MDCO
| – | – |
-2,000
| Closed | -$72K |
|
|
CORI
33
DELISTED
Corium International, Inc.
CORI
| – | – |
-1,425,000
| Closed | -$13.6M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, Tamarack Advisers held 33 positions worth $245M, down 30% from $350M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Tamarack Advisers withdrew a net $36.6M in Q4 2018, closing 12 positions and reducing 4 holdings. Its most notable exit was Labcorp, an estimated $27.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Tamarack Advisers opened a new position in Portola Pharmaceuticals, Inc. worth $7.81M.
- Tamarack Advisers's largest Q4 2018 buy was Portola Pharmaceuticals, Inc.: 400,000 shares worth $7.81M.
- Tamarack Advisers added most to Veradigm Inc. Common Stock in Q4 2018, an estimated $12.3M increase.
- Tamarack Advisers's biggest Q4 2018 reduction was Hologic, cutting an estimated $6.15M.
- Tamarack Advisers fully exited Labcorp in Q4 2018, selling an estimated $27.8M.
- Tamarack Advisers's ten largest holdings make up 80% of its $245M portfolio in Q4 2018.
- Tamarack Advisers opened 3 new positions and closed 12 in Q4 2018.
- Tamarack Advisers's portfolio value fell 30% quarter-over-quarter to $245M.
Based on Tamarack Advisers's 13F filing for Q4 2018, filed 11 Feb 2019.